(Q36278291)

13 August 2017

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia (English)

1 reference

13 August 2017

0 references

1 reference

Dirk Blom

7

0 references

Michel Krempf

object named as

Michel Krempf

9

0 references

Richard Češka

object named as

Richard Ceska

5

0 references

John J. P. Kastelein

1

object named as

John J P Kastelein

1 reference

13 August 2017

Henry N Ginsberg

2

1 reference

13 August 2017

Gisle Langslet

3

1 reference

13 August 2017

G Kees Hovingh

4

1 reference

13 August 2017

Robert Dufour

6

1 reference

13 August 2017

Fernando Civeira

8

1 reference

13 August 2017

Christelle Lorenzato

10

1 reference

13 August 2017

Jian Zhao

11

1 reference

13 August 2017

Robert Pordy

12

1 reference

13 August 2017

Marie T Baccara-Dinet

13

1 reference

13 August 2017

Daniel A Gipe

14

1 reference

13 August 2017

Mary Jane Geiger

15

1 reference

13 August 2017

Michel Farnier

16

1 reference

13 August 2017

1 September 2015

1 reference

13 August 2017

European Heart Journal

1 reference

13 August 2017

36

1 reference

13 August 2017

43

1 reference

13 August 2017

2996-3003

1 reference

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Decade in review--dyslipidaemia: Resurgence of targets and compounds to treat dyslipidaemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

PCSK9: a key modulator of cardiovascular health

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4644253

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV370

Lipoprotein(a) Levels in Familial Hypercholesterolemia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV370

Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26330422

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26330422

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/EURHEARTJ/EHV370

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26330422

1 reference